AMYLYX-HOSTED KOL EVENT AT OBESITYWEEK 2026 - AMYLYX PHARMACEUTICALS INC
everyone. Welcome and thank you so much for joining us today, both here in the room as well as on the webcast. I'm Camille Bedrosian, Chief Medical Officer at Amelix. We are so excited to be here at Obesity Week as well as having the opportunity to share with all of you the aspects of post-bariatric hypoglycemia as well as the potential of Avexatide, an investigational first-in-class GLP-1 receptor antagonist with FDA breakthrough therapy designation. Throughout today's program, you'll hear from leading PBH experts as they discuss the burden of PBH, the unmet need, as well as the Phase III lucidity results in more detail. Before we begin, as you know, we will be making some forward-looking statements during the presentation, so please refer to the slide that you're seeing here, as well as to the information that's on our investor website. So here is the agenda for today. First, we'll begin with a short video, very important to hear from a member of the PBH community who shares with us her experience living with the condition. It will raise quite a bit of awareness about what people live through with this condition. Next, we'll hear from Dr. Zeb Saeed from Brigham and Women's Hospital, who will provide an overview of PBH, including patient burden, clinical challenges, and ongoing unmet medical need. Then we'll hear from Dr. Marilyn Tan, who will review the lucidity results presented earlier today at Obesity Week and share her perspective on the clinical significance of these results. Following these presentations, Jamie, our SVP of Medical Affairs, will moderate a discussion and Q&A session with our experts that includes both their comments as well as questions from all of you here in the room as well on the webcast. Before we begin, I do want to share a few key themes for today's discussion to level set everyone. First, PBH is a debilitating condition with no approved treatments, and that has a profound impact on patients' quality of life. Secondly, in lucidity, Avexatide demonstrated consistent, highly statistically significant, and clinically meaningful reductions in hypoglycemic events across all endpoints. you'll hear that further from Dr. Tan. Third, based on the strength and consistency of the data, we do believe that Avexatide has the opportunity to potentially change the practice in PBH. So before we begin and dive further into the science and the clinical data, we'd like to share a patient perspective. Patients' experience actually taught us a great deal about PBH as we were understanding more about Avexotide as well. And it is the center of everything we do and what we will be discussing today. The following video shares the experience of one member of the PBH community. So let's take a look. my name is maria and i was diagnosed with post-bariatric hypoglycemia in 2021 i had ruin y bariatric surgery back in 2019 i've always really struggled with my weight as i got older i started developing some health issues my life before surgery was not really life. I couldn't walk 20 feet without having to sit down. My physician told me that my best option for survival was bariatric surgery. I knew that I was limited on time if I didn't do anything, and I wanted to be here for my family. The bariatric injury was a big deal for me. Surgery exceeded my expectations. I went from existing to living. I lost 120 pounds in the first seven months after the surgery. I was no longer on any medications whatsoever for my blood pressure or anything else. I was out and about doing things that I had not done in decades. Life after surgery was amazing. After my mom had bariatric surgery, it seemed like she was finally getting to live her life where she never really had that opportunity before. The very early signs and symptoms of PBH that I had starting in 2020 were just feeling really tired after I ate. And I started experiencing some issues with standing and suddenly feeling like if I didn't go lay down, I was going to fall down on the floor. My mom and I were in the kitchen together and she starts shaking. She goes down to the ground. I started typing in bariatric surgery all of her symptoms that she's feeling finally found this article and it was like this aha moment like okay we found it post bariatric hypoglycemia is what we found I called my primary care physician and she referred me to an endocrinologist when my endocrineologist told me that there were no approved treatments for post-bariatric hypoglycemia, it was a huge blow. It was devastating. Regardless of what it is that I eat, it will send my blood glucose into a spike. As soon as it hits its peak, it suddenly makes a turnabout and drops like a rock. Whatever I correct with, usually some form of a food or juice. My body reacts to it and I spike again and I drop again. And sometimes you've lost an entire day of just battling this. I have watched my mom go from this hopeful spark, going on adventures, having a wonderful time, embracing this new life to a very deep depression. The uncertainty of when my glucose is going to plummet is debilitating. I can't make plans because I don't know if I'm going to be able to complete that task safely. This isn't the life I was dreaming of. It's just, I'm existing again. my endocrinologist put me on a medication for chronic weight management it doesn't help with all of the symptoms of post-bariatric hypoglycemia for me unfortunately i do still have the brain fog i do Still have the spikes and the drops the need to lay down after i eat is all still there so it's still debilitating for me. Being able to have a little bit more confidence in the fact that I could enjoy my life again would be overwhelming. I do not regret having that surgery. I am sitting here today because of that surgery. My hope is that one day there will be a cure for post-bariatric hypoglycemia. If we can't get a cure, at least an adequate treatment that will address the symptoms of PBH. Thank you for listening, and now it's my great pleasure to introduce Dr. Zaid, who will discuss PBH in more detail. Thank you, Zaid. Thank you. I'm here with Dr. Pedrosian, and good afternoon, everyone. My name is Aibajah Saeed. I'm an endocrinologist at Brigham and Women's Hospital, and I was one of the investigators of the LUCIDITY trial, and it's my great privilege to be a part of this discussion for a disease that has essentially been unrecognized and unaddressed for too long. So while I talk about post-periatric hypoglycemia, or PBH, I thought it would be helpful if we start with our historical context of our evolution of understanding this disease. So in 1966, Dr. Edward Mason at the University of Iowa performed and pioneered the first bariatric surgery for obesity. Now, up until then, gastric surgery was being performed, and hypoglycemia after gastric surgery was been recognized as late dumping syndrome that was happening one to three hours after. But it wasn't until 2005, where there was a landmark case series published in the New England Journal of Medicine, which showed severe, it was six individuals, they had severe post-RNY gastric bypass hyperinsulinemic hypoglycemia. And at that time, it Was thought that perhaps it was beta cell hyperplasia that was at play, because these individuals underwent distal and partial pancreatectomy. But soon after, this was debunked, and what was found was that it's not beta cell hypoplasia hypothesis. In fact, that's not perhaps at play. But the real study came in 2014, which was a key mechanistic study in which nine individuals were given exendin-939, which is a GLP-1 receptor antagonist, later on became a vexatide. And this was given intravenously to nine individuals during a mixed meal tolerance test, and their blood sugars were seen, as well as the GLP1 and insulin. And what was seen was that in all nine individuals, the hypoglycemia abolished and insulin levels decreased by half and then in 2017 the American Society of Metabolic and Bariatric Surgery published a position statement mentioning post-bariatric hypoglykemia and that's a great step in the right direction but it's still mentioned as PBH being rare and what I'll show and what we'll talk about is also that it is definitely from what our own anecdotal and also other research experiences that it ist underdiagnosed and it's not as rare as we thought. With that, let's talk about the key driver, like I mentioned. So we have mechanistic studies showing GLP-1, but how does GLP1 cause hypoglycemia? So the first thing that I want to recognize is that we know there's altered gastrointestinal anatomy after 2NY and nutrients go into the small intestine rather rapidly because they're bypassing the stomach. So this does two things. First, there's rapid glucose absorption, which causes that spike that you saw even Maria mentioning. And also, GLP-1 is made by the intestinal L cells, an exaggerated GLP1, in response to the nutrients coming fast. And what this results is that there's GLP 1-mediated insulin release by the pancreas. So there is this hypersecretion of insulin in the bloodstream, which is more than what the glucose needs at that time. So there's this mismatch that's happening. And then there is that drop. As you can see at the right here, there is this rapid drop in glucose right after. So this spike and drop pattern typically happens around one to two hours or three hours after a meal. And what happens is that it's recurrent, right? So you're, in order to correct the hypoglycemia, patients then have glucose or other things, and that results in that same pattern of increase in spike and then drop. One thing I do want to mention is that we know the GLP-1 after Roux-en-Y gastric bypass does increase, and it's actually helpful and helps with some of the metabolic complications and the benefits of the Roux en Y gastric by-pass surgery. However, what's happening here is really a maladaptive process. In terms of prevalence, so in 2026, there was a model-based estimate estimating around 160,000 people in the U.S. estimated to be living with PBH requiring medical management. However, this is an estimate, and what we do know, the prevalence really depends on how it's diagnosed. And we also know that, in fact, one-third of patients with a history of Roux-en-Y gastric bypass or sleeve gastrectomy have reported symptoms of hypoglycemia. It doesn't mean all of them have PBH, but it really does underscore that perhaps this is underdiagnosed an underappreciated condition. The clinical diagnosis is based on a clinical suspicion and then confirming that the glucose is in fact low. And what we know is that there are many reasons why this might be underdiagnosed or have delayed diagnosis. First is the presentation itself could be delayed. So symptoms typically happen a year after doing a gastric bypass. It could be years after the surgery that the symptoms first develop. The second thing, and it's really important to recognizes, the symptoms could be very nonspecific. You heard from Maria that the first symptoms that she had was just feeling tired and fatigued after surgery, after eating. And so the symptoms can be attributed to just feeling tied, having anxiety, just feeling fatiguing, and not really to hypoglycemia, both by patients but even sometimes by providers. The next step is the fact that there's mistesting. So even if someone is recognizing something is off, people don't have glucometers at home or CGMs at home to see. So unless they're asking their healthcare providers or providing that information or the healthcare provider is asking, they wouldn't be actually getting tested. In fact, a lot of patients that I've seen were first diagnosed because they were in the hospital for something else and they got their blood drawn and their glucose was in the 40s and 50s and then backwards, oh, were you having symptoms? Oh, how long have you been having symptoms? And they might have been having symptoms for years before the diagnosis was made. And then lastly, this concept of hypoglycemic unawareness. We know that the symptoms of, like I said, could be very nonspecific. So some people don't even think that they're having something. And when you're constantly having these hypoglycaemic episodes, over time, your body gets used to it and you don't have those early autonomic symptoms. And so that's referred to as hypoglysemic unawareness, where you don'T really have the warning symptoms. The first thing that you're having is something catastrophic, like passing out or loss of consciousness or something of that sort, like what happened essentially with Maria. And I can tell you as an investigator on this study, when we were recruiting for this study, we kind of threw a wide net and just reached out to all individuals who had had Roux-en-Y gastric bypass in our institution, asking if they had symptoms and then assessing them. And what we saw was a lot of people, whether or not they participated in the trial had true hypoglycemia with blood sugars going in the 20s and 30s, and they just didn't know. Which brings me to the symptoms. So I've kind of already mentioned, but the symptoms really can be divided into two big categories. One is the autonomic symptoms, which happened earlier on. Not everyone has them, but it's the warning. So it's the increased sympathetic nervous system, so sweating, palpitations, anxiety, just feeling tired. The neuroglycopenic symptoms happen when there's decreased glucose to the blood. So usually when the blood glucose is lower, though it could happen even at higher levels, it includes confusion, impaired cognition, and the ones that we really worry about, such as loss of consciousness, seizures, blurred vision. And we know it's not good for your brain not to get glucose. And when there are recurrent episodes of this neuroglicopenia, we know this can result in cognitive impairment, increased risk of falls, increased accidents. And like I said, some people have hypoglycemic unawareness because they've not really put two and two together. Nobody really asked them. And neuroglycopenia may be the first recognized symptoms. And this is important because this has real impact on people's life. The lack of independence. You heard from Maria, I don't do things anymore because I don' t know when it' s going to happen. So there's increased psychological distress, worse quality of life, reduced productivity because they can't have a fully functional job. Safety concerns, including driving, involves, in one small study, over 90% of people with PBH self-reported living with a disability. So huge burden. so despite having this huge burden unfortunately the current management is suboptimal and we do not have any FDA approved therapies for PBH so diet is the mainstay but it requires a lot of restrictive eating so eating less carbs eating 30 or less carbs with every meal so that there's less carbohydrates going into the intestines mixing carbohydrates with fat and proteins so that there's lower transit but a it's difficult to sustain b sometimes my patients have sensory concerns or they just don't like certain foods so just it seems very restrictive to them the other thing is even if they're doing all the right things many people still have symptoms and that's when we go to off-label medications which have variable efficacy variable tolerability so again they don't work for a vast majority of people and surgical intervention is really the last resort which would involve including reversal of the Roux-en-Y gastric bypass which would undo all the other metabolic benefits that you were getting in the first place. So really, there's persistent gaps in treatment. Patients continue to experience sudden and inconsistent and unreliable hypoglycemic events despite active management, which really underscores the significant unmet need for the control of symptoms and address the underlying disease mechanism. So I want to end by saying The PBH I've shown, Maria has talked about, can significantly impact daily life, but PBH management is limited and inconsistent. So these are exact quotes from the qualitative interviews that were performed in the lucidity trial when asked to describe the hypoglycemic events. And what you can see here is someone mentioning that they had to close their work and their daycare because they couldn't take care of children as part of their job. Some people could not be able to do their work or were fearful of driving because they would have such severe symptoms. And what I want to point out here and what I hear most of my patients, it's not just you have a hypoglycemic event and it's just one event. It ruins the day because they keep on happening and your entire day is just chasing that blood sugar. And it can also let you feel very exhausted, as said very eloquently by this participant. So what we're talking about is a disease which results and impacts people's independence, their livelihood, their quality of life, their physical and their psychological well-being, and is really underscoring the unmet need for treatment of PBH. With that, I will give to Dr. Tan who will talk about the lucidity trial. Thank you, Dr. Said. For those that are not in the room, my name is Marilyn Tan. I'm a clinical professor of medicine and a clinical endocrinologist at Stanford University School of Medicine. I was involved in prior Avexatide trials, and I am the principal investigator of the Lucidity trial. For Those who attended my presentation earlier this morning, please bear with me. You'll have to hear it again. But today, I'm excited to present the results of Lucidity, the phase 3 pivotal trial of Avexetide for the treatment of post-bariatric hypoglycemia, or PBH. PBH is a chronic metabolic condition that's characterized by an exaggerated GLP-1 response that occurs after bariatric surgery. This results in hyperinsulinemic hypoglysemia, typically occurring 1 to 3 hours after meals, and PBH can develop months to years after surgery. While historically the prevalence has been challenging to determine, current estimates are that about 12% of those undergoing Roux-en-Y gastric bypass and about 5% of those undergoing sleeve gastrectomy will go on to develop PBH that requires medical management. PBH is associated with a significant clinical burden with critical effects on patient safety, daily living, and long-term health. Now, going back to this critical role of GLP-1 in PBH, as Dr. Saeed mentioned, after bariatric surgery and other surgeries as well, there is altered nutrient transit. This then leads to an enhanced activation of the intestinal L-cells, which then leads to an exaggerated GLP1 response. Following this is an excessive insulin response that then leads to postprandial hypoglycemia. In addition, there are other factors that may trigger these episodes, including stress and physical activity, all contributing to the unpredictable and challenging nature of post-bariatric hypoglycemia. Now on the right here, this really nicely shows this GLP-1 response. You can see here in the gray are the non-surgical controls, and after a mixed meal tolerance test, there's a slight rise in the GLP1 level. Then in the blue here, you can see these are patients who have undergone gastric bypass but do not have hypoglycemia. And they have an enhanced GLP-1 response, which is often desirable in this population. However, if we look in the red here at our PBH patient, you see this very high GLP1 response that far exceeds that of other surgical patients. And I'd like you to keep this curve in mind as we move on to the next slide. Now, seeing that role of GLP, it provides a clear therapeutic rationale for GLP-1 antagonism in the treatment of PPH targeting the underlying mechanism or one of the underlying mechanisms. Anavexatide is an investigational first-in-class GLP1 receptor antagonist that has been shown in five prior clinical trials to reduce hypoglycemia across multiple measures. What I'd like to focus on on this slide, though, is this mechanistic study that really demonstrates how GLP-1 receptor antagonism attenuates that hyperinsulinemic hypoglycemia that we see in PVH. So on the right here, again, we're looking at a mixed meal tolerance test. And again, in the gray are the non-surgical controls. And you can see that the glucose rises slightly after the meal and the insulin rises and the glucose settles out. Now in the blue here, this is our bariatric surgery patient who had that enhanced GLP1. And as Dr. Saeed noted, there is a mismatch. And so initially there's a little bit of a rise of a glucose, but in these patients, the glucose levels settle out. They're not high, they're not low. Now back to our PBH patient. If you recall that very significant GLP-1 spike, that preceded this significant rise in plasma insulin levels that we see here. And that results in the hypoglycemia occurring at starting at about 60 minutes after the meal. Now, if we look in the dark blue here or black, that is our PBH patient with a vexatide. You can see that the post-meal insulin level is actually brought down to essentially match the non-surgical control and those gastric bypass patients who do not have hypoglycemia. And importantly, on the bottom here, you can see that that hypoglycemia is prevented. So importantly, this really nicely demonstrates that GLP-1 receptor antagonism is not a full blockade of GLP1, but rather mitigation to restore physiologic levels and to prevent hypoglykemia. Now for the phase 3 lucidity trial design. Lucidity is a multicenter randomized double-blind placebo-controlled trial in patients with a history of Roux-en-Y gastric bypass and a clinical diagnosis of PBH. Participants were not allowed to be on medications that altered glucose metabolism. And prior to the run-in, all participants received structured dietary counseling for medical nutrition therapy, which is a cornerstone of the management of PBh. In addition, they received unlimited test strips so that they could check their finger stick glucoses, as well as blinded continuous glucose monitors, or CGMs, which did have safety alarms. During the 21-day eligibility run-in period, participants had to have at least three qualifying events with at least one hypoglycemia event being a Level 3 event adjudicated by an independent adjudication committee. Following this, those who qualified were then randomized three to two during the 16-week double-blind treatment period to either Avexatide, 90 mg subcutaneously once daily with medical nutrition therapy, or Placebo, subcutaneously once daily, with medical nutrition therapy. Following this is a 32-week open label extension, which is ongoing. During the 16-week double bind period, the primary efficacy endpoint was the composite rate of SMBG level 2 hypoglycemic events as well as blinded EAC adjudicated level 3 hypoglycemic events. Now as a refresher, level 2 hypoglycemia is defined as a glucose of less than 54 milligrams per deciliter, and a level 3 event is a hypoglysemic event that involves altered mental and or physical functioning, thus requiring external assistance for recovery. We also assessed multiple other complementary endpoints, and you can see here the pre-specified secondary endpoints are listed. These included the level 2 hypoglycemic events by SMBG, the level 3 hypoglycemic events by EAC, the level two hypoglycemic events by blinded CGM, and also the percent change from baseline and composite level 2 and 3 event rate. 78 participants underwent randomization with 47 randomized to avexatide and 31 randomized to placebo. Retention rates were high. Over 90% of patients completed the 16-week double-blind period, and all of them went on to the open-label extension. Now for the baseline characteristics, you can see that they were generally well-balanced. But what I would really like to highlight here is this disease burden that Dr. Saeed and Dr. Bedrosian talked about earlier. You can see that prior to entering the trial, about two-thirds of patients had daily hypoglycemia symptoms. Nearly half of these patients had a history of loss of consciousness from PBH, and almost 30% of the patients had an history of hospitalization due to hypoglycemia from PBJ. This section really highlights the significant clinical burden and the unmet need for this disease. Now, Avexatide met the primary endpoint, as you may all have heard. Avexatide reduced the composite level 2 and 3 hypoglycemic event rate by 55% compared to placebo, with a p-value of 0.000034. These results were also consistent across the pre-specified sensitivity analyses and the predefined subgroups that you see here on the lower right. Looking at it a different way, how did Avexatide impact patients compared to their own baseline? On the left here, you can see that Avexetide reduced the composite of levels 2 and 3 hypoglycemia event rates during the 16-week period by 72.9% compared to baseline. This is in contrast to the placebo group, which reduced it by 37.8%. Now, I'd like you to consider the placebo group in the context of the trial design where we really offered the patients a high level of support. Patients had not only structured dietary counseling as well as frequent check-ins to make sure they were adhering to the diet, unlimited supplies to check their glucoses, alarms on CGMs which they may not have had. And so really this is the gold standard of care. And the reality is that for these patients, many of them don't have access to sometimes even any of these in the community. But even in this highly supported environment, we still saw a very significant improvement in hypoglycemia event rates with Avexatide compared to placebo. All pre-specified multiplicity-controlled secondary endpoints were met with robust significance. And looking at the mean weekly event rate over the double-blind treatment period, you can see that Avexetide reduced level 2 SMBG events by 63% compared to placebo. Avexatide reduced level 3 hypoglycemia events by EAC by 47% compared to placebo. And Avexetide reduced Level 2 CGM hypoglykemia events by 42% compared with placebo. All of which support this robust primary endpoint result. Avexotide was generally well-tolerated. While there were slightly more drug-related treatment-emergent adverse events in the Avexatide group, discontinuation rates were low and were actually the same in the two groups. The most common treatment emergent adverse events were gastrointestinal and injection site-related. For GI side effects, diarrhea was the most common, usually mild to moderate, and often resolving while on study. Similarly, the injection site rejections were generally mild to moderate and often resolving while on steady. Notably, there were no serious treatment-related adverse events, and no deaths. Now, we're at obesity week. Everyone's talking about GLP-1s, and so we have to wonder about the effects on weight and glucose, right? No clinically meaningful changes were seen in body weight nor fasting plasma glucose through week 16. In fact, at week 16, over 91% of patients in the Avexetide group had a body weight within 5% of baseline or lower, which exceeds that of the placebo group. In conclusion, Avexatide, an investigational GLP-1 receptor antagonist, reduced the composite of levels 2 and 3 hypoglycemic event rates by 55% compared to placebo, thus meeting the primary endpoint. These reductions were consistent across SMBG level 2 events, level 3 hypoglycemia events by EAC, as well as level 2 event by CGM. All of this supports the primary result. Avexatide was well-tolerated with mild to moderate GI and injection site reactions, often resolving while on the study, and there were no significant changes in body weight or fasting plasma glucose. This really builds upon the five prior clinical trials of Avexetide to support the reproducibility of the safety and efficacy of GLP-1 antagonism for PBH. It also further supports that GLP-1 signaling is key in the pathophysiology of PBH. So lucidity really represents a landmark study, and for a disease with such significant clinical burden but no FDA-approved therapies, this really provides an exciting and important advancement. Okay, and now I'll pass it on to Dr. Timmons. Hello, everyone. My name is Jamie Timmons. I'm the Senior Vice President of Medical Affairs, and I'll be moderating our Q&A. For those of you who are not in the room, I'm joined on the stage by all of our speakers. So we have Dr. Tan, Dr. Saeed, and Dr. Bedrosian. A few housekeeping items before we get started for those ofyou in theroom. If you have a question, please just raise your hand. We will come to you with a microphone. Please wait to get the microphone to speak your question just so everyone listening in can hear you if you're calling in online please submit any questions via the portal Courtney will share them with me and please include your name and your firm and in your question just we know who asked it with that let's get started hi this is another from ACV and right I have one question for dr. Sayed and two questions for Dr. Tan. Dr. Sayed, now that you have Alexatide and potentially, you know, will be approved in a couple of months, how do you plan to address the diagnostic challenge? Dr. say, that's a great question. I think there's multiple layers for it. What we, in other words, what I'm referring to is we know that it's underdiagnosed and it's underappreciated. And I think the education needs to be at every level. The best model I can think of is a Swiss cheese model, which is like a safety model. In other words, you have different layers of systematic protection. So it would include even before bariatric surgery with the surgeon explaining that this is a risk, recognizing people may not remember it, but then afterwards reiterating the risk. If they're being discharged from the clinic, making sure that they're aware this might happen later. Then the other key stakeholders are the patients. So just patient information. We live in a world where patients have a lot of information and they are empowered to know these things. So in terms of just knowing for the patients to know that this can happen is great. The next is, like I said, a lotof these patients are diagnosed much later when they are not seeing specialists. So it's either primary care doctor or someone who's seeing them for weight management or an endocrinologist. So ensuring everyone is aware of this disease. And then the other thing that needs to happen on a system level is a consensus guidelines. Currently, it's a clinical diagnosis. There are some guidelines in the making. I was very excited, which is why I mentioned the ASMBS statement, position statement for 2017. But there needs to be more consensus guidelines for the diagnostic accuracy. One additional thing I will say is that it's exciting that as of October of this year, we do have an ICD code for post-periodic hypoglycemia, which we didn't even have. So I think everything is heading in the right way. And I'm very excited about the future. Great. Thank you. Dr. Tan, how do you think 47% reduction of, you know, the level three or neuroglycopenia symptoms seen with avixotide translate in real world that's my first question the second question is given the stochasticity of you know the of the disease and the avixote data can physicians or patients now really have a control of their hyperglycemia two three events or at least in a position to be you know where they are predictable like where they can predict you know, whether they can think about this disease control in a predictable manner on top of SOC. So for your first question, I mean, level three hypoglycemia events are admittedly very challenging to capture in a clinical setting, right? These patients have lived with life-threatening hypoglykemia for years, and the natural tendency is not to go reach for a glucometer when you're shaky with blurred vision, and then try to line up your test strip, and dann get just the right amount of blood and then go log your events in an e-diary that has to be adjudicated by a committee so i admit it's hard to capture the events but it was important for the rigor of the study and regarding the sorry your second question was predicting predicting yeah so so as you can see actually when we compare it to each individual's baseline the reduction with Avexatide was almost 73% in the hypoglycemia events. And I will share that in some of my prior studies, I've had patients who had no hypoglykemia while on drug. And so it's very promising. And in this population, I mean, think about how desperate people are with off-label use for even, you know, 5%, 10% improvement. So to see, you know 73% compared to baseline and then 55% in the double-blind treatment period compared to placebo is really compelling. Hello, this is Zach Dunn from Guggenheim on behalf of Jameis Fernandes. Thank you for the questions and congratulations on the full data set. Very exciting. And so just to start with, for the CGM measurements, I know in the phase two it was cut up over different times, is that result over 24 hours and also thinking about the different physicians that take care of these patients based on our conversations and even some I've had at this conference it seems that the endocrinologists and the academics understand this concept of raising glucose whereas some obesity docs where some pbh patients may be they're so used to lowering blood glucose, is how do you address these different practitioners in terms of raising awareness and encouraging them with the potential benefits of a vexatide? Thank you. So in termsof the question around the CGM endpoint, that is 24 hours. And then around kind of the clinical practice and that discussion there, I'll definitely love to hear our clinicians, but I think it's really important to always go back to the principle of what are we trying to treat in PBH, which is the hyperinsulinemic hypoglycemia, severe events as categorized by the ADA that are considered a medical emergency. And so always going back to that principle of what we're managing here in this particular condition. But Dr. Tan, would you like to start there in your clinical perspective? Yeah. So to your point about the fact that it really does require multidisciplinary care, including not only from a treating physician or advanced practice provider, also the dieticians and others involved in the care, right? Like maybe somebody has PBH and then they're trying to get an elective knee surgery and the surgeon has no idea and doesn't know what this disease is. So that all goes back to increasing the awareness. But I think you're right in that it has to be a complete mindset shift, right. These patients started out with obesity. Some of them may have had pre-diabetes or diabetes, and the focus is always on preventing hyperglycemia. But in fact, now the bigger problem is the hypoglycemia, which I always tell patients one severe event that's low could be much more dangerous than an occasional higher glucose. Thank you, Dr. Tan. And I'll just add to that. You're absolutely right. in terms of raising awareness, it's also in terms of dietary modifications. I've had people where they thought they were having lows, so I just need to eat glucose all the time. And that's so counterproductive because then you keep on having these spikes and lows. The other thing I would say, just anecdotally talking to even my colleagues and other colleagues in the community is the fact that there is no current therapy for treating PBH is also a deterrent right we all went into medicine to help people and we don't have a good treatment right now so unfortunately that also plays into well you have this condition I don't know how to treat you or I have these things which may help so I do think that this will sort of be the impetus to kind of increase awareness of the disease itself because potentially there might be a therapy that is on label and FDA approved for it while we have a little um pause here and questions coming in um one one question that we often hear is more at the individual patient level in terms of you know how how have your patients felt in the study and now that we're in the ole and we know that everyone is on active uh we're safe to kind of comment there. So Dr. Tan and Dr. Saeed, would you like to just share what you've heard from your participants? Yeah, absolutely. I mean, it's been such a privilege and so humbling to be a part of this study. I've seen various response. I have had participants where they've cried because they didn't think that this would be possible. I had participants when they initially were participating in the study, it was like, what do I have to lose? So coming from a place of like even hopelessness and not really trusting that this would work, the realizing, oh my goodness, I don't believe this actually works. So, you know, I feel like we're in this unique position that we've been with our participants through this journey and will continue to do so. But it's been really, really humbling to see this experience. Yeah, and I'll just add that during the double-blind placebo-controlled period, I had many participants where when they entered the study, they said, okay, I'm on drug. I know it. And I said, I don't know, right? And then we went on to open-label extension, and then they said oh my god, now I'm really on drug, and so, you know, we wanted to keep it blinded in the beginning. I think there were concerns about unblinding, but actually in the begining, I mean, we chose patients who had never been exposed to a vexatide, they didn't know how they could feel. And maybe some of it was the benefit of the dietary management, but, you know, in the beginning, patients really didn't know. And then once they are on drug, they feel it, right? This is a very symptomatic disease. And so once you get a single dose of the medication, you see the glucose effect and you feel the symptoms changing. And Maybe a question from the online queue. So the first one comes from Jarway Fang with Citi, and I think this is for both Dr. Tan and Dr. Saeed. Which patients would you prioritize for a vexatide at launch, and what clinical features would make treatment most urgent? Dr. Tam, would you like to start? Yeah, so in our study, I would say these were kind of more moderate patients, although I will add that there is a much more severe population of patients who couldn't even enter the study, right? These are the patients who just cannot give up their continuous glucose monitors that they rely on so heavily to prevent lows. They're the ones that get maybe 5-10% benefit from other off-label therapies but just can't afford to wash out and go through the run-in and then potentially be on placebo for 16 weeks. So there's a large population that we didn't even capture in this study and certainly those are high priority patients. But I will add that even those patients who may be reasonably controlled with a very restrictive diet, I would offer the Avexatide to them for a couple of reasons. One, some of my patients actually have legitimate severe protein calorie malnutrition from being so restrictive with their diets and they need to gain weight. The other is that the diet is so restrictive that patients tell me, I cannot eat a slice of pizza with my son. I can't go to a birthday party. And the goal of Avexetide in those patients would be to restore some normalcy and quality of life and maybe some predictability for them. I'll let Dr. Saeed comment. I really don't have much to add. Absolutely. So I would say for people who are unable to either follow the dietary recommendations or where the dietary recommendations don't work is the people that I would be seeing potentially being on Avexadide. Because really, at the end of the day, this is the first in-class drug which is looking at and really targeting the mechanism, which up until now we haven't had. Great. We'll ask another one from the online portal. So this one comes from Dina Ramdhani from B of A. Her question is, diarrhea occurred in 30% of patients on a vexatide versus 10% on placebo, while injection site arrhythmia, bruising, and pain occurred in 19%, 17%, and 13%. How would you counsel patients about daily treatment, and what proportion might discontinue in routine practice? Hold on, the question. Answer that part. Great. So just to recap, give a little additional color to the adverse event data that we see in lucidity. So in terms of the diarrhea, most diarrhea was grade 1 mild diarrhea, and all ISRs were either grade 1 to 2, so mild to moderate, for both of these most resolved in the trial while remaining on Avexatide. So I'll turn over to our clinicians just to speak more to how you see managing potential AEs in clinical practice. Dr. Saeed, why don't we start with you? Sure, absolutely. So the truth of the matter is, even for the off-label therapies that we have, they have all a lot of tolerability issues. So they're already navigating. Second is the burden of the disease is so much. I really do not anticipate this being an issue for mild diarrhea, which is self-resolving while on therapy or injection site reaction to be something that will ward off people and not want them to take a medication that can potentially make them feel so much better and improve their quality of life, which istimilar to what we saw in the clinical trial. And the third is we are, as doctors, we're used to helping patients manage these side effects. So I also don't anticipate this being a problem amongst healthcare providers to help patients navigate these side affects. Yeah. As Dr. Saeed pointed out, with the current off-label therapies, tolerability and efficacy are significant issues where we're just short, right and so the diarrhea again was generally mild to moderate and often resolving while on treatment and keeping in mind these are treatment emergent adverse effects and over the week 16 week period people may develop diarrhea going back to the injection site reactions it could be you know one time where there was a little bit of blood it got reported or it could be something a little more serious but i will say that with all injections we will see some injection site reactions. And again, in my three prior clinical trials of Avexetide and during this study, I personally have not had any patients discontinue the drug due to the injection site reactions. Great. I think we have another question in the room. On the motivation aspect, what was your experience with the motivation aspect for two injections a day in this patient? Were they like very willing to take two injections every day or, you know, some clarity on that thought would be good. Dr. Tan, do you want to start? Yeah, so for the one injection a day subcutaneously, I will say that these patients did not have any hesitation. I do think that the GLP-1 agonists and medications for osteoporosis and various other medications that now come in injection form have helped to destigmatize the injection mechanism. But furthermore, I'll say that the adherence, despite the injection being daily, is actually very high because we're looking at a very symptomatic disease. If you miss a dose of your osteoporosis medication, you're not going to feel it. You're probably not going to fracture the next day, right? But if you miss the dose of your vexatide, you will have that symptomatic hypoglycemia. And being a symptomatic disease, I think, really helps with adherence. Camille. I just wanted to clarify, you were talking about two injections. Yes. Yeah, yeah. So it's one dose, but in the early part of the trial, the double-blind period and part of OLEA, there were two injections, 45 milligrams each, that were given at not exactly the same time, but sequentially so that i believe is what to what you were referring and uh in the larger part of the ole it was a single injection because we changed the vial configuration maybe a follow-up question on i know in endo there was this uh poster on the real world economic effect of you know the pbh right given the data now like is there any analysis have you done like how that kind of impact that real world impact yeah you know the real world effect um also when are we going to see some quality of life data from that i can i can take those um so in terms of your first question yes we absolutely have um updated the the model that was presented at endo with the kind of data and assumptions from lucidity and we we will be sharing that um soon next year but it generally looks good as I'm sure you can expect we see a decrease in the overall burden in terms of cost etc and then I'm sorry I spaced on your second question quality of life yet so quality of five measures we are following in the open label extension and so you know those measures other exploratory measures as well as the same measures that were shared earlier today we will we will look through all of those in the open label extension and share those when we have the data. Thank you. Chris Jenner, Rock Springs Capital. I think many of us here in the audience are, you know, kind of very much focused on how this will do commercially, right? And so there's been a lot of discussion about the significant unmet medical need and the need for education and the various physician groups that take care of the medicine. So to that end, could you just speak to in your respective practices, is there an ongoing effort right now to kind of identify, as is often the case when a first-in-class medicine becomes available, who's going to get the medicine first? how are they going to be identified, and what is the kind of normal cadence for patient visits who you might describe are kind of just getting along, navigating, but clearly would be ones who would benefit from Avexatide. So if you could kind of talk about your individual practices and talk about the number of patients you have and say, okay, off the top of my head, I could see X number, you know, we're trying to have an accelerated program to bring them in, and then others, we can wait and maybe get some patient experience, but could you give us a sense of how you think the next like 12 to 18 months will play out after the medicine becomes approved? Thank you very much. Great. So I think it'd be great to hear from both of you. Dr. Saeed, would you like to start? Sure. I will say there's a lot of hypotheticals in that scenario. So let me think through. In terms of giving you an exact number, I can't give you an exact number of how many people do I anticipate in my clinical practice or in our entire clinical practice to be on Avexadide. The typical practice for any new drug, so I'm thinking of for osteoporosis or for other things is first of all awareness amongst the providers so we usually have our CMA meetings which are pretty regularly and ensuring everyone is aware of the data because not everyone is just making sure everyone is away off the data and making sure every one is familiar there is usually one or two champions so one of two prescribers who are who know more so those are the people who could be referred to. And then in terms of patient identification, that can vary. Most of the times it might be when they're coming back for the routine visit, but it might быть people that, you know, immediately, we all know of at the top of our head, I can think of people that I'm taking care of clinically who are having such a burden of disease that I remember and that I might be reaching out to soon. And that's what I would expect most of my colleagues to do the same. Yeah, so I actually have, in our electronic medical record, you can create various patient lists. I have patient lists for those with PBH from Roux-en-Y gastric bypass, those with VSG, and those with other surgical subtypes. So clearly I've been thinking about this for the last 10 plus years since I started investigating abexotide. And in addition to those, at least at Stanford, I actually personally get at least one or two new referrals each week for PBH which I don't take into my clinic because I just I'm at capacity and I actually have a list of those separately and I do know that many of my patients are excited so whereas for the patients who were just you know kind of getting by we've exhausted all therapies I would usually see them maybe every six months and now they've been asking to be seen every three months because they're waiting to find out when they might be able to qualify for an expanded access program or when they might be able to get on the list to be able to get some sort of treatment. Again, when there's no other treatment, I think the adoption tends to be much earlier, right? It's not like you're looking at your fifth hypertension medication or something like that. Going to take another question from the online portal. This comes from Chris Chen from Baird. For Dr. Tan, are there any fundamental differences between the two types of surgeries, sleeve gastrectomy and Roux-en-Y gastric bypass, that you think may contribute to a differential effect of Avexatide, or do you think Avexotide's efficacy would be roughly similar in the two populations? And can you elaborate on why you think PBH occurs in less than half as many sleeve gastrectomies patients, around 5%, versus Roux and Y gastric by-pass, around 12%? So Dr. Tang? Okay. So the anatomy is obviously different. The weight loss tends to be a little bit less with VSG patients or sleeve gastrectomy patients compared to Roux-en-Y gastric bypass patients. But again, we don't fully understand all of the predisposing factors for why people develop which disease. And so a surgeon could better explain the exact differences in terms of the surgical technique. But as you noted, we do see PBH more in the Roux and Y gastric bypass population. However, multiple mechanistic studies have shown that in sleep gastrectomy patients, as well as patients with other upper GI surgeries, they have a very similar exaggerated GLP-1 response owing to this altered nutrient transit. And in fact, in the phase 2b study of Avexetide, I did study patients who had undergone total gastrectomie as well of sleeve gastrectomies. And actually, we had looked at the composite of level 2 and 3 hypoglycemia events, the same endpoint that we're looking at here today in lucidity. And when we teased out those gastrectomy and VSG patients, we saw that their response was just as robust as it was in the Roux-en-Y gastric bypass patients, because I really wanted to make sure that the results were not just driven by the RYGB patients where we have more data. So it would be great to get more data on these patients. And the ones that I have in my clinic are waiting to see if they can get into some study. this is uh zach dunn from guggenheim thank you again so i guess can you share a little more color on the patients that didn't meet the entry criteria so we can kind of understand how that process works and along those same lines how do you envision the workup for a patient to then be on a vexatide it seems it would be the only drug approved but do you vision potentially stepping through a CARBOS or some of these other off-label therapies. And then lastly, any, the latest on the EAP, if you can give us an update there. Thank you. Okay. So let's start with those who did not meet eligibility and then I'll start and hand over to our investigators. So in terms of those who did not meet eligibility, it's really a reflection of the study design and the rigorous nature of who we were trying to enroll in the study as opposed to do you have PBH or don't have PBH. It was really around meeting that run-in event rate as well as, really importantly, being able to capture those events in terms of finger-sticking at the right time, using the e-diary correctly, et cetera. So that was really what we saw in terms OF those that weren't meeting eligibility. It was a function of their ability to capture events from that perspective. I'll hand over to our investigators there, and then we can come back to the EAP. But any other color that you'd like to add there around those who didn't meet criteria? Yeah, so as we noted, the capturing of the events was very challenging, right? So who here has used a glucometer? It is very difficult, right, your classic symptoms of hypoglycemia, like blurred vision, tremulousness, altered mental status. And we ask that these patients who have been living with this disease and accustomed to just reacting to the hypoglycemia, we are asking them to pause and treat it completely differently and go get their glucometer, try to match up the blood to that tiny test strip and get just the right amount of blood, and then go into an e-diary and enter all of their symptoms and write a story about what happened, which then has to be adjudicated by another committee. And it's a lot to ask of the patients. It's a pretty significant burden on them, I will admit, but it was necessary for the rigor of the study. and so it's very difficult to capture these events and in addition I have patients where they don't even tolerate a glucose of less than 54. One of my patients literally passes out at a glucose in the 60s and so capturing these events for the sake of the study was challenging. I'll let you comment on that before we move on to kind of the stepwise. I had a very similar experience. I've had participants where they freaked out because they tried 20 different times to use it and they were Like, will I run out of my test strips because I still couldn't capture it? So absolutely. It was not a question of whether or not they had PBH. It was whether they have enough insulin severity. And the second thing is, can we capture it. And it was just hard, which still obviously was important for the rigor of the study. With regards to the stepwise approach, I think dietary modifications will be the gold standard for all people. that is not going to change because that is and that was part of the lucidity trial and that's something that is inherent again going to the pathomechanism that lesser carbs mixing it with protein and fat means less nutrients in the intestines now in terms of off-label versus effects tight anytime when you can do an on-labor therapy most doctors would tell you that they would want to use something that has been fda approved off-level as a band-aid that we use because we don't have available therapies. But again, at the end of the day, it will be every patient is different who is sitting in front of you, share decision-making, discussing the risks and benefits, a pill versus an injection. These are all the benefits. This is on label. This is what was seen. And at the End of the Day, what matches with what's in alignment with patients' goals and what their needs are. And I'll add that while there have been publications on the medical nutrition therapy, I actually don't think there are great studies assessing the effect of the medical nutrition therapy, which we actually demonstrated nicely in our placebo group. But of course, it's a cornerstone of the therapy for the patients. It's absolutely necessary. And then kind of the elephant in the room, the unofficial acarbose use, right? This is our kind of unofficial first-line off-label medication. I mean, first off, I don't know if insurance companies can mandate an off- label medication as a first step. Icarbose is pretty benign, right? It's inexpensive. It can cause GI side effects, but the main concern is just that it's not effective. And so after that, as Dr. Saeed said, with the tolerability and coverage and efficacy issues of everything that's off-label, why would you reach for something off-label if there is an on-lable option that targets one of the underlying key mechanisms of the disease? Great. And then for EAP, so we don't comment on specific numbers on our ongoing programs, but I will say that we've had a large amount of interest in access to Avexatide. Just between Dr. Tan's presentation earlier today and me getting over to this hotel room, I talked to three different physicians who were requesting access for their patients. And so we are looking into expanding the eligibility criteria so that more people are eligible for the EAP, and more to come there soon. Maybe we'll take another question from the online portal. This one comes from Rami Kathkuda with LifeSide Capital. First, he wants to say congrats on the update. And then he has two questions. I think first, can you provide more color on the distribution of hypoglycemic event reductions across patients? Was the treatment benefit broadly consistent or driven by a subset of patients with particularly high baseline event rates? And then secondly, can you touch on how quickly the treatment benefit emerged, and did you observe continued improvement or any attenuation in efficacy over time? So in terms of the first question, we do not see the effect being driven by any small subgroup or small portion of patients. As you saw from the results, the robust statistically and clinically meaningful difference is, you know, seen across the participants in the study. And then in terms of the second around how quick we see an effect and the durability of effect, looking at this, we do see, and as Dr. Tan shared, pretty quick onset in terms of the effect of Avexetide, and over the 16-week double-blind period did not see any waning in that effect. Any additional questions in the room? So our friends online can hear. Dr. Tan, on the screen failure rate, like the 78 screen, what were the characteristics of the screen failures rates? What was the conditions on which you kind of educated? Yes. To the point we mentioned earlier, a large portion of the screens failures were really around the event rate and ability to capture the event rate those things really went side by side so it wasn't necessarily just did you have three events over the three-week run-in period it was more could the participant actually use the devices correctly follow the procedures correctly and get those events captured and so that was the majority of reasons for screen failure in the study the rest were kind of 1Z, 2Z, just not meeting specific eligibility criteria. And maybe we'll take one final question online. This one comes from Jacob Ormus from TD Cowan. I know we talked earlier about sort of which patients you would potentially prescribe Avexatide to, but in practice, you know, what threshold would prompt you to prescribe of exotide, recurrent level two events despite dietary therapy or a carbose, a prior level three event, or a certain number of events per week? Is it a combination of these? And any thoughts on translatability of compliance in the real world setting? Great. So I think let's hear from both of our clinicians. Dr. Tan, would you like to go first? Yeah. So, um, I'd like to address the compliance one first, just because I have strong thoughts on this, that in asymptomatic disease, people are adherent because they feel it if they're not. In terms of the number of hypoglycemic events, it's not something said. A lot of this is shared patient decision-making, right? Talking to the patient about their situation, what their needs are, what they've failed, and what they're willing to tolerate and what They would like to do. But certainly all of those would be qualifiers, whether they're having daily hypoglycemia or level two, despite medical nutrition therapy or any level 3 event, those are all very clinically important and potentially dangerous scenarios. I completely agree. I don't think there is a certain threshold that I would say you would have to meet to be, as a gateway, to be prescribed this if a vexatide gets approved. It's really for each individual patient, their own tolerance. If someone has one level 2 hypoglycemia even once a month, but it's really affecting their quality of life, they can't go to work that day, it's important. So it really comes to the patient and also discussing the side effects and shared decision making at the end of the day. But I wouldn't gatekeep it. Great. So that concludes our Q&A. Thank you, everyone, for your thoughtful questions, both in the room and online. I'll hand it back to Camille, who's going to bring us home with closing remarks. Great. Well, thank you to both Drs. Tan and Saeed for your great insights and perspective. We really appreciate all you shared with us today. It was very meaningful and very helpful as well. And I also thank all of you in the room and on the web for your great questions. Very helpful and very thoughtful questions as well, so thank you very much for that. Let me just go here, closing remarks. Here we go. You heard today about the significant unmet need in PBH, and I think there's no doubt based on what we heard from Maria as well as the comments made today by our experts. In addition, you saw tremendous data, results shared by Dr. Tan here today and earlier as well. Highly statistically significant, clinically meaningful, meeting all secondary endpoints on the background of five prior clinical trials that also are highly significant. Truly an important setting here. And then we are on track for our NDA submission. We, you know, our sense of urgency has redoubled since we received the top-line data from Lucidity. And as you heard, there are people also who wish to have access to Avexatide, which we are doing through our EAP. So, and then finally, although we didn't discuss it too much, we are executing on our launch plan should Avexotide be approved, and we're on track with those as well. So thank you so much. I will just say that for those in the room, please don't hesitate to take a box lunch as you exit, and do enjoy the rest of Obesity Week. Thank you so very much again. Thank you.
- Company
- AMYLYX PHARMACEUTICALS INC
- Keywords
- AMYLYX PHARMACEUTICALS INC